Clinical Trials Logo

Depressive Symptoms clinical trials

View clinical trials related to Depressive Symptoms.

Filter by:

NCT ID: NCT05897827 Completed - Depressive Symptoms Clinical Trials

PLANTS Pilot Trial

PLANTS
Start date: June 28, 2023
Phase: N/A
Study type: Interventional

This pilot cluster-randomized controlled trial will evaluate the PLANTS (Providing LGBTQ+ Adolescents with Nurturance, Trustworthiness, and Safety) course among high school staff. The primary hypotheses are that the PLANTS course will have high acceptability, usability, appropriateness, and feasibility as reported by high school staff.

NCT ID: NCT05861414 Completed - Depressive Symptoms Clinical Trials

Intervention Effect of Emotional Working Memory Training on University Students With Depressive Symptom

Start date: October 11, 2022
Phase: N/A
Study type: Interventional

Objective: To investigate the effects of emotional working memory training (EWM-T) on depressive symptoms and rumination among university students. Methods: The experimental group comprised 25 participants who underwent 21 days of emotional working memory training, which involved viewing a continuous stream of negative emotional face content on a grid and remembering the faces and locations presented on the grid. The control group consisted of 25 participants. The Beck Depression Inventory-II (BDI-II), the Chinese version of the Character-Digital Breadth Test, and the Ruminative Responses Scale (RRS) were used as the pre- and post-test indicators.

NCT ID: NCT05793736 Completed - Pain Clinical Trials

Prevention of Long Covid Syndrome

Start date: February 2, 2023
Phase: N/A
Study type: Interventional

Biofeedback equipment is classified by the Food and Drug Administration (FDA) as medical device class II and this type of equipment/treatment has shown evidence regarding stress management in post-Covid-19 syndrome. The main objective of the study is to verify the feasibility of an HVR biofeedback training protocol in patients with long covid, and also to verify improvement induced by the technique in relation to: cognitive performance; pain perception; fatigue; quality of life; depressive and anxious symptoms

NCT ID: NCT05703776 Completed - Depressive Symptoms Clinical Trials

Physical Exercise and Depressive Symptoms in Moderately or Severely Depressed Adults

EXIMOS
Start date: January 19, 2022
Phase: N/A
Study type: Interventional

This study is a comparative trial comparing the time course of depressive symptoms between moderately and severely depressed participants over a 10-week long exercise program

NCT ID: NCT05702086 Completed - Depressive Symptoms Clinical Trials

Making SPARX Fly in Nunavut: Pilot Testing an E-intervention for Boosting Resilience Against Youth Depression

Start date: September 8, 2014
Phase: N/A
Study type: Interventional

The goal of this pilot trial was to test SPARX with Inuit youth in Northern Canada. SPARX is an educational video game designed to teach cognitive behavioural therapy strategies and techniques. This "serious game" has previously shown promise in addressing symptoms of depression with Māori youth in New Zealand. Researchers in this study tested SPARX's suitability with Inuit youth in the territory of Nunavut using surveys that youth completed before and after gameplay. Hypothesis 1: Youth who completed SPARX were expected to experience a decrease in depressive symptoms and risk factors related to depression. Hypothesis 2: Youth who completed the SPARX program were expected to experience an increase in factors related to resilience. A team of Nunavut-based community mental health staff facilitated youth's participation in this remote pilot trial with 24 youth aged 13-18 across 11 communities in Nunavut. These youth had been identified by community facilitators as showing low mood, depression, and/or significant levels of stress.

NCT ID: NCT05686408 Completed - Depression Clinical Trials

Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)

UPLIFT
Start date: March 2, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).

NCT ID: NCT05676658 Completed - Anxiety Clinical Trials

Effects of Coherent Breathing Breathwork on Health

Start date: February 22, 2023
Phase: N/A
Study type: Interventional

The investigators are conducting a randomised-controlled trial comparing coherent breathing at ~5.5 breath cycles per minute-bcpm (with equal inhalation/exhalation durations of ~5.5secs each) to a well-designed placebo (paced breathing at 12bcpm with equal inhalation/exhalation durations of 2.5secs each). The metric of 12bcpm is in line with guidance from the British Journal of Nursing, Royal College of Physicians, and Johns Hopkins University which state that the average, healthy bcpm should range from: 12-20bcpm, 12-18bcpm, and 12-16bcpm, respectively, hence the investigators chose the minimum/lower bound for the active placebo control group. The main questions that our study attempts to address are: Does coherent breathing (and placebo coherent breathing) lead to improved mental health and wellbeing in a general population adult sample? The study will be conducted entirely online through the research platform Prolific, so participant data will be anonymous. The investigators will collect self-reports of mental health and wellbeing before and after the four-week breathwork period, along with a follow-up one-month later. Pre-post intervention and follow-up questionnaires will be completed online via the survey platform Qualtrics which will be linked to Prolific. Participants will also be asked how many times they practiced out of the assigned 28 days, to gauge self-reported adherence to the protocol. The investigators can then observe whether self-reported adherence correlates with changes in mental health and wellbeing, if any. Data on the self-reported credibility/expectancy of the breathwork randomly allocated to participants will also be collected, along with open-ended responses on participants' overall experience of the protocol/study.

NCT ID: NCT05652803 Completed - Depressive Symptoms Clinical Trials

Bibliotherapy-based Psychoeducation Program the Effect of Elderly Individuals on Depression and Hopelessness Levels

Start date: December 22, 2022
Phase: N/A
Study type: Interventional

Bibliotherapy has been mainly focused on the social and emotional problems of children and young people, and studies with the elderly are very few. Based on the suggestion of meeting the right book with the right individual, which is the basis of bibliotherapy, it is predicted that the bibliotherapy method can be useful in reducing depression and increasing hope in the elderly, with the selection of books that are suitable for the cognitive levels of the elderly.

NCT ID: NCT05627206 Completed - Anxiety Clinical Trials

The Impact of PM+For Moms Intervention on Improving Mother's Mental Health in Zambia (PM+FM)

PM+FM
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

CMHD are particularly prevalent among women, posing a major threat to their own and their children's wellbeing. Despite the high prevalence of CMHD and the existence of effective treatments, interventions supporting women living in low-resourced settings remain limited. This study builds on a parent study (Zamcharts NCT03991182), which identified a high prevalence of women with anxiety and/or depression. We propose to design, test, and validate a community-based intervention nested within the public primary health system in Zambia, to identify and treat women with mild-to-severe CMHDs.

NCT ID: NCT05615948 Completed - Clinical trials for Major Depressive Disorder

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

Start date: December 6, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.